MHLA-DR expression was strongly reduced by plasma from COVID-19 patients with immune dysregulation but not healthy controls [130,142]; the effect could be partially restored by the addition of the IL-6 blocker Tocilizumab [142]. This evidence concerns the gene IL6 and COVID-19.